RT Journal Article
T1 Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment.
A1 Giner, Mercè
A1 Vázquez-Gámez, María Angeles
A1 Miranda, María José
A1 Bocio-Nuñez, Jesús
A1 Olmo-Montes, Francisco Jesús
A1 Rico, Miguel Angel
A1 Colmenero, Miguel Angel
A1 Montoya-García, María-José
K1 Denosumab
K1 Teriparatide
K1 circulating osteogenic progenitor cells
K1 metabolic bone disorders
K1 osteoporosis
AB Circulating osteogenic precursor (COP) cells are peripheral blood cells with a capacity for osteogenesis. The objective of our study was to ascertain the percentage of COPs as an early biomarker of osteoporosis and the effect of these cells in response to Denosumab (DmAb) (anti-resorptive) or to Teriparatide (TPDP) (anabolic) as very effective drugs in the treatment of the illness. A first study was conducted on healthy volunteers, with three age ranges, to determine the percentage of COPs and relate it to their anthropometric and biochemical characteristics, followed by a second longitudinal study on patients with osteoporosis, whereby one group of patients was treated with TPTD and another with DmAb. All were analyzed by cytometry for COP percentage in blood, bone turnover markers, and bone mass. Our findings show that COPs are influenced by age and become more prolific in the stages of growth and skeletal maturation. A higher percentage of COPs is found in osteoporotic disease, which could constitute a predictive marker thereof. We also show how treatment with TPTD or DmAb mobilizes circulating osteogenic precursors in the blood. Significant increases in % COPs were observed after 12 months of treatment with Dmb (21.9%) and TPTD (17%). These results can be related to an increase in osteogenesis and, consequently, a better and more efficient repair of bone tissue.
SN 2077-0383
YR 2022
FD 2022-08-14
LK http://hdl.handle.net/10668/21335
UL http://hdl.handle.net/10668/21335
LA en
DS RISalud
RD Apr 9, 2025